1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Welcia Holdings Co., Ltd.

Welcia Holdings Co., Ltd.

WLCGF
Welcia Holdings Co., Ltd.US flagOther OTC
16.41
USD
- -
- -
3.42BMarket Cap
2012 Y
2013 Y
2014 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7,939.43
4,505.67
4,386.91
1,355.02
1,497.67
1,670.35
1,869.81
4,159.5
4,552.61
4,924.86
5,477.2
5,892.51
6,205.1
5,987.44
Basic EPS, GAAP
159.64
103.33
95.27
24.43
34.73
41.24
41.81
109.23
134.23
126.98
129.38
128.04
72.23
106.17
Free Cash Flow per Basic Share
-36.18
290.19
71.09
12.43
48.98
51.4
44.93
261.38
153.1
-18.84
193.83
136.36
170.71
- -
Dividend per Share
19.08
12.46
15.11
5.27
5.92
8.05
10.56
22.08
27.13
30.18
31.12
33.46
35.43
- -
Book Value per Share
640.64
409.84
531.88
139.1
159.18
192.31
223.35
533
640.49
738.13
834.37
938.31
973.07
978.02
Tangible Book Value per Share
912.86
546.71
749.94
245.61
264.14
279.29
300.3
693.68
771.54
874.57
919.67
994.37
1,021.14
1,023.23
Basic Weighted Avg Shares
37
74
82
390
416
416
417
209
209
208
209
207
207
207
Sales/Revenue/Turnover
293,378
334,393
360,797
528,402
623,163
695,268
779,148
868,280
949,652
1,025,947
1,144,278
1,217,339
1,285,005
1,236,907
Operating Margin (%)
3.92
3.77
3.94
3.55
3.86
4.15
3.73
4.35
4.53
4.19
3.99
3.55
2.83
3.02
Depreciation Expense
5,339
6,549
7,135
10,283
11,953
13,266
14,496
15,663
16,975
18,961
23,225
24,392
26,248
- -
Net Income, GAAP
5,899
7,669
7,835
9,527
14,451
17,166
17,423
22,802
27,999
26,453
27,030
26,451
14,958
21,934
Effective Tax Rate (%)
47.68
33.96
39.44
42.49
37.69
36.08
39.23
36.94
32.4
37.63
39.28
34.7
45.43
37.68
Profit Margin (%)
2.01
2.29
2.17
1.8
2.32
2.47
2.24
2.63
2.95
2.58
2.36
2.17
1.16
1.77
Working Capital
-4,138
-6,920
716
5,281
8,300
9,302
1,103
6,969
12,841
18,974
26,064
37,120
44,274
40,634
LT Debt
11,101
12,284
11,381
14,447
15,767
28,249
27,872
28,209
33,628
44,556
63,646
59,484
55,788
55,876
Total Equity
42,791
50,275
70,806
103,776
116,231
130,480
143,946
162,416
180,349
207,885
232,383
244,364
254,484
253,879
Return on Invested Capital (%)
9.63
11.91
10.21
9.5
10.82
11.55
9.54
11.74
13.02
10.4
9.09
8.53
5.88
6.93
Return on Capital (%)
13.6
14.96
12.54
13.27
17.36
16.77
13.8
16.03
17.04
13.23
11.19
9.83
5.6
8.02
Return on Common Equity (%)
27.99
28.36
21.13
19.45
23.99
23.47
20.13
22.32
22.87
18.41
16.48
14.37
7.57
11.27

Capital Structure

FRC

•

in mil. unless spec.
Feb'24
May'25
Aug'25
ST Debt
23,215
24,430
21,814
LT Borrowings
27,386
26,507
24,746
LT Finance Leases
32,098
31,152
31,130
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
207
207
207
Market Capitalization
- -
- -
495,692

Working Capital

FRC

•

in mil. unless spec.
Feb'24
May'25
Aug'25
Total Current Assets
259,601
265,455
325,744
Cash, Cash Equivalents & STI
30,533
36,457
82,752
Accounts Receivable, Net
63,197
65,555
80,453
Inventories
137,092
144,146
140,121
Total Current Liabilities
222,481
230,301
285,110
Payables & Accruals
- -
- -
- -
ST Debt
23,215
24,430
21,814
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.14%
9.48%
4.14%
Free Cash Flow
-80.3%
-258.08%
25.49%
Net Income, GAAP
9.83%
-5.23%
-43.45%
Sales/Revenue/Turnover
14.03%
8.17%
5.56%
Total Cash Common Dividend
20.71%
9.95%
6.15%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
298,267
312,750
299,443
306,879
1,217,339
2025
304,734
325,851
- -
- -
1,285,005
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
24.56
- -
- -
- -
128.04
2025
13.67
- -
- -
- -
72.23
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
33.46
2025
- -
- -
- -
- -
35.43
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Hideaki Kirisawa
Full Time Employees
15,286
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
2-2-15, Sotokanda Tokyo Japan 101-0021
IPO Date
Dec 14, 2021
Website
welcia.co.jp
Similar Companies
Kobo Biotech Ltd. (KOBO.BO)
Fredun Pharmaceuticals Limited (FREDUN.BO)
Dechra Pharmaceuticals PLC (DCHPF)
Sundrug Co.,Ltd. (SDGCF)
Ohki Healthcare Holdings Co.,Ltd. (3417.T)
Auro Laboratories Limited (AUROLAB.BO)
Business
Welcia Holdings Co., Ltd. operates as a holding company that manages subsidiaries engaged in the retail of pharmaceuticals and related products through a nationwide chain of drugstores in Japan. The company offers prescription drugs and pharmaceuticals; over-the-counter medicines; hygiene care and nursing products; baby supplies; health foods and supplements; cosmetics; household sundries; and food items, primarily serving individual consumers via its extensive store network concentrated in the Kanto region and other areas across Japan. Founded in September 2008 through the merger of Welcia Kanto and Takada Pharmacy, Welcia Holdings is headquartered in Chiyoda-ku, Tokyo, and maintains capital stock of 7,792 million yen with approximately 16,600 employees. In recent developments, the company has pursued aggressive expansion via strategic acquisitions, including Xchange Inc. in March 2024, Towoshiya Pharmacy Co., Ltd. in June 2024, Welpark Co., Ltd. in September 2024, and WELCIA PARTNERS Co., Inc. (formerly TEPCO Partners) in October 2024, alongside full and medium-scale renovations of over 170 stores to enhance profitability. As of December 2025, Tsuruha Holdings Inc. has completed a share exchange, establishing Welcia Holdings as its wholly owned subsidiary as part of a capital and business alliance with AEON Co., Ltd. and Tsuruha, forming Japan's largest drugstore group with combined annual sales exceeding 2 trillion yen.